For specialty, home infusion, long-term care, retail and 340B pharmacies, and the health systems that own them, where one wrong HCPCS unit costs more than a month of dispensing margin.
Get a free revenue cycle assessmentPharmacy revenue cycle management is the end to end financial process behind every drug a pharmacy dispenses or administers: benefit investigation, prior authorization, acquisition and 340B designation, charge capture, coding, claim submission, remittance posting, denial work and underpayment recovery. Pharmacy billing is one stage inside it, the claim itself.
Most specialties bill one benefit. A pharmacy bills two, and the same molecule can belong to either. Over the counter it adjudicates against the pharmacy benefit in seconds on the NCPDP standard. Given in a clinic, an infusion suite or a hospital outpatient department it becomes a medical claim, priced from a HCPCS code and paid weeks later. The drug did not change. The claim format, the price basis, the authorization route and the appeal path all did. That fork separates this work from pharmacy billing services, which start once the format is settled.
New York moved the pharmacy benefit for mainstream managed care members to NYRx on April 1, 2023 and left physician administered J-code drugs with the plan. California carved pharmacy out to Medi-Cal Rx on January 1, 2022, but only partially for physician administered drugs: the same product routes to Medi-Cal Rx on a pharmacy claim and stays with the plan on a medical claim. A group operating in New York and California runs two rulebooks for one drug, and a misrouted claim rarely rejects cleanly. It pays zero, or it pays and gets recouped.
Acquisition cost changes on the wholesaler's schedule. Payment changes on the ASP file's. A pharmacy repricing once a year is wrong for three quarters of every year, and the gap never surfaces as a denial. The remittance still looks like a payment.
Five minutes with your own reports. Three of these true means the leak is structural.
Recognise three or more of these in your own numbers and the problem is the process, not the payer.
Get a free assessmentTwo pharmacies of identical revenue can have nothing in common operationally.
Seven stages, each with a failure mode specific to drugs. Three happen before a claim could exist.
Decide which benefit pays before the drug is ordered. Fails when the plan is checked for eligibility but not for which side covers the product.
Get the approval and record what it approved. Fails when the number is saved and the approved drug, dose, unit count, site and date range are not.
Buy on the right account. Fails when a 340B purchase lands on an ineligible patient, or a GPO purchase on an eligible one, discoverable only later.
Turn what was given into a charge the same day. Fails when an administration is documented clinically and never becomes a charge.
Convert the dose into HCPCS billing units and attach the NDC and modifiers. Fails when units are copied from the vial, dose or package.
Send it, then reconcile the remittance to the claim line. Fails when payment posts and balances, hiding a rate below contract.
Work denials by root cause. Fails when high dollar denials are rebilled unchanged, producing a duplicate and burning timely filing.
Organised by cause, not by code, because each fix sits in a different department. Ranges assume a pharmacy collecting about $2 million a year on medical benefit claims.
| Leak point | Codes or rule | What goes wrong | Annual dollars at risk | Luxen audit finding |
|---|---|---|---|---|
| Wrong benefit, wrong claim format | State carve-out scope, NYRx and Medi-Cal Rx | A physician administered drug goes out on a pharmacy claim, or the reverse | $40,000 to $90,000 | Benefit routing was wrong on 11% of specialty drug claims |
| Units taken from the vial, not the code | Claims Processing Manual chapter 17 section 70, where code J1745 bills in 10 mg units | Units copied from dose or package, so every line errs one way | $35,000 to $110,000 | HCPCS units did not match the amount administered on 9% of claims |
| Discarded drug never reported | Modifiers JW and JZ on single dose containers, code J0178 for example | Waste documented, never billed, or the line edits out | $18,000 to $60,000 | No JW or JZ modifier on 12% of single dose container drug lines |
| Approval expired before the date of service | Payer reauthorization windows | Scheduled off the calendar, not the approved date range | $50,000 to $130,000 | Authorization had lapsed at the time of service on 14% of specialty and infusion claims |
| Unclassified drug codes sent bare | Codes J3490 and C9399, unclassified drugs and biologicals | No NDC, strength or invoice in the narrative, so it prices at zero | $15,000 to $55,000 | Unclassified drug lines went out without supporting detail on 8% of submissions |
| Underpayment nobody reads | Contracted rate against the current quarter ASP file | Pays under contract, posts clean, never disputed | $25,000 to $75,000 | Underpaid drug lines were found on 6.4% of paid claims across 19 pharmacy billing reviews |
We will tell you which of these leaks is open in your practice, free, in 30 minutes.
Book the reviewNo federal dataset publishes days in AR, net collection rate, clean claim rate or cost to collect for pharmacy. On those rows Typical is measured at intake across Luxen client practices and Target is what they reach after onboarding, so both columns are Luxen data. The last row is federal.
| Metric | Definition | Typical | Target |
|---|---|---|---|
| Days in AR | Average age of open receivables from date of service | 54 at intake | 33 or fewer within 120 days |
| Net collection rate | Collected dollars over the contracted allowed amount | 91.4% at intake | 97.8% by month six |
| Clean claim rate | Share accepted on first submission, no rework | 89.6% at intake | 97.3% or better |
| First-pass denial rate | Share denied on first adjudication | 14.2% at intake | 6.1% or lower within 90 days |
| Cost to collect | Fully loaded billing cost as a share of what it collects | 8.6% of collections, across 19 pharmacy billing reviews | 3% to 6% of collections |
| Drug claim error exposure | Paid dollars failing a CERT style review | 8.4% for Part B overall, CERT FY2025 report, claims July 2023 to June 2024 | Under 3% on audited drug lines |
Typical values come from the named federal source in the table intro. Target values come from Luxen client data.
From January 1, 2026, impacted payers must decide expedited prior authorization requests within 72 hours and standard requests within 7 calendar days, must state a specific reason for every denial, and must publish authorization metrics annually, the first posting due by March 31, 2026. That binds Medicare Advantage organizations, Medicaid and CHIP fee-for-service and managed care, and qualified health plan issuers on the federally facilitated exchanges. It does not apply to drugs. Read that as written: the single largest front-end burden a pharmacy carries was carved out of the relief. Nothing external is about to shorten these queues, so staff them as permanent capacity rather than as a backlog you will clear, and build the authorization headcount into the operating budget rather than treating it as a project.
Initial approvals mostly get done, because somebody is waiting on them. Renewals fail quietly. The approval sits in a portal, the refill or infusion sits on a schedule, and the two are never joined. In the 2026 Luxen Pharmacy Revenue Cycle Audit, authorization had lapsed at the time of service on 14% of specialty and infusion claims. None of those were coverage disputes. They were calendar failures, which makes them the most recoverable dollars on this page, because the therapy was appropriate and the patient was eligible.
An approval number on its own is not an authorization record. Capture the approved product and strength, the approved unit count, the approved site of care, the exact date range, the reauthorization trigger, and the peer to peer contact if one was used. Then drive the schedule from the date range rather than from the fill calendar, so a booking outside the window is blocked before the drug is drawn rather than denied after it is given. Our eligibility and prior authorization team works that queue against the schedule, not against a spreadsheet. Where the site of care changes, treat it as a new authorization question, because a plan that approved a hospital outpatient department has not approved a home infusion.
This is the most expensive misunderstanding in pharmacy revenue. The Medicare Claims Processing Manual, chapter 17, section 70, is explicit: where HCPCS is required, units are entered in multiples of the units shown in the HCPCS narrative description, so a code described in 50 mg with 200 mg given is 4 units. Where the NDC is required, units follow the NDC label description instead. Two denominators for one administration. Copy the vial count, the milligrams or the package quantity into the units field and the line is wrong every time, in the same direction, and it passes every internal audit checking the claim against the same wrong source. That is why certified coders derive units from the descriptor rather than from the chart.
Inside a health system the charge description master is owned by finance, updated on someone else's cycle, and carrying codes deleted quarters ago. Pharmacy finds out through a denial. Get read access to the drug section, reconcile it against the current quarter's HCPCS file, and own the exception list even where you do not own the master. The same applies wherever drugs and administration bill together, including oncology.
On separately payable Part B drugs supplied in single dose containers, one of two modifiers must appear: JW to report the discarded amount on its own line, or JZ to attest that nothing was discarded. JZ became required on July 1, 2023 and claim editing followed on October 2, 2023. This is not only a claim rule. Under section 1847A(h) of the Social Security Act, manufacturers owe Medicare a refund where discarded amounts exceed an applicable percentage of 10 percent of total charges for a drug in a quarter, and CMS issued the first refund reports in December 2024, covering more than $139 million. Your JW reporting is the input to that calculation, so an unreported waste line is both revenue you did not bill and data you did not contribute.
Part B pays separately payable drugs at 106 percent of ASP under 42 CFR 414.904, and CMS reposts the ASP file and the NDC to HCPCS crosswalk every quarter, so a contract written as a percentage of ASP reprices four times a year whether anyone looks or not. A biosimilar pays at its own ASP plus 6 percent of the reference biological's ASP, not 6 percent of its own, and for a qualifying biosimilar the Inflation Reduction Act raised that add-on to 8 percent of the reference ASP for five years, running October 1, 2022 to September 30, 2027 for products already paid on an ASP basis as of September 30, 2022.
Section 340B(a)(5)(A) of the Public Health Service Act, at 42 U.S.C. 256b(a)(5)(A), prohibits duplicate discounts: a covered entity may not seek Medicaid payment for a drug purchased at the 340B price where the state also collects a manufacturer rebate on it. The exposure lands in two separate places in the cycle, and most pharmacies watch only one. The first is purchase account designation, decided before the drug leaves the shelf. The second is claim identification, decided when the claim is built. Get the first right and the second wrong and the compliance problem is identical, which is why 340B belongs in the revenue cycle rather than beside it.
On separately payable Part B drugs, covered entities report modifier TB, effective January 1, 2025, on the claim lines that previously carried JG. JG was in use from 2018 through 2024. The switch is simple to describe and easy to miss in a charge master nobody reconciles quarterly, which is the same failure mode as a deleted HCPCS code and usually the same root cause: no owner, no cadence, no exception report.
Every contract pharmacy arrangement adds a reconciliation obligation: dispenses matched back to eligible patients, eligible prescribers and eligible encounters, at a cadence fast enough that an error is correctable rather than repayable. Treat that as a revenue cycle stage with an owner and a deadline, not as an annual audit exercise. A finding that surfaces at audit is a refund. The same finding at 30 days is a correction.
From January 1, 2026, hospitals encoding a negotiated charge as a percentage or an algorithm must publish the 10th percentile, median and 90th percentile allowed amounts in dollars under 45 CFR 180.50, drawn from 835 remittance data. That is the first public distribution to test a drug payment against. Our denial and AR recovery team works the gap by payer, as a batch rather than one remit at a time.
The 2026 Luxen Pharmacy Revenue Cycle Audit. 3,900 pharmacy medical benefit claims re-adjudicated line by line, plus 19 pharmacy billing reviews, January 2025 through June 2026. On each claim we counted benefit routing, whether HCPCS billing units matched the amount administered, whether a discarded drug modifier was present where required, and whether an active authorization covered the date of service.
Cite as: The 2026 Luxen Pharmacy Revenue Cycle Audit, January 2025 through June 2026.
A hospital-affiliated specialty and infusion pharmacy, about $4.1 million a year in medical benefit collections, after two quarters of falling cash on flat volume. We took the drug lines first.
Reported by the Director of Pharmacy Revenue Integrity, whose internal audits ran against the same charge build that produced the unit error, so they had checked the wrong number for two years.
Same pharmacy: $2,000,000 in annual medical benefit collections, a 14.2% first-pass denial rate at intake and 54 days in AR. Every figure is arithmetic you can redo.
Net, year one: $129,600 of recurring collections recovered, plus about $86,100 released once from AR, against $90,000 in fees and $130,800 you stop spending.
Want this arithmetic run on your own collections and denial rate?
Run my numbersOur fee is a share of what we actually collect on the claims we work: 3% to 6%. Nothing on top. No setup fee, no exit fee, month to month, 30 days notice either way.
On $2 million of medical benefit collections that is $60,000 to $120,000. Included at either end: benefit investigation, authorization and reauthorization, coding and unit derivation, submission, posting, denial work, appeals and underpayment recovery. We set the rate after the free 30 minute assessment, and it does not move afterwards without a new agreement.
For a pharmacy collecting $2 million a year on medical benefit claims. In-house assumes one full-time biller plus a half-time authorization coordinator, the smallest staffing covering both benefits.
| Line item | In-house | Luxen |
|---|---|---|
| Fully loaded staffing, 1.5 FTE | $118,000 | Included |
| Billing and clearinghouse software | $9,600 | Included |
| Coding reference and quarterly file maintenance | $3,200 | Included |
| Denial rework and appeals capacity | Absorbed, first to be dropped in a busy week | Worked by root cause |
| Coverage during leave and turnover | Nothing moves | Continuous |
| Annual total | $130,800 | $60,000 to $120,000 |
One benefit, one state, low specialty volume and a biller of five years standing: keep it. Outsource when the medical benefit side is a side job for someone whose main job is the counter. Open biller roles took a median 67 days to fill (Luxen Practice Manager Survey 2026). Compare medical billing companies by state before you commit.
No ranked list survives contact with your own claim mix. A scoring sheet does. Weight these, score each candidate out of five, and require evidence.
Two findings for that conversation: 52% of practices that switched billing vendors cited missing denial reporting as the main reason, and 63% could not name their top three denial reasons (Luxen Practice Manager Survey 2026).
You have an incumbent. That is the normal case and it is not an obstacle. We sign the BAA before anyone touches your systems, take read access to the pharmacy system and the medical claim path, and start on the oldest unpaid drug claims while the incumbent keeps working current volume. Nothing migrates and nobody changes software. Claims are being worked about two weeks from signed BAA, and first recovered payments arrive about three weeks after that. The overlap runs as long as you want. Most practices end it once the first full month of reporting lands and the denial reasons stop being a surprise.
We work inside the pharmacy system and the claim path you already run. No migration, no new software, BAA signed before access. Automate in this order, because each step makes the next worth doing. First, benefit and eligibility checks ahead of the order, since a wrong benefit poisons everything downstream. Second, authorization end dates wired into the scheduling calendar as a hard block. Third, quarterly reconciliation of the charge master's drug section against the current HCPCS and ASP files. Fourth, unit derivation validated against the code descriptor at charge entry. Fifth, remittance-to-contract comparison that flags underpayments on its own. Denial prediction comes last, since it learns nothing from a claim file full of avoidable unit errors. Submission sits inside full-service medical billing.
Benefit investigation, prior authorization, acquisition and 340B account designation, administration and charge capture, coding and unit assembly, submission and payment posting, then denial work and underpayment recovery. Three of the seven happen before a claim exists, which is the part pharmacies staff last. Stage five is where the Medicare Claims Processing Manual, chapter 17, section 70 rule bites: HCPCS units are multiples of the code descriptor, not of the amount dispensed.
Any ranked list reflects someone else's claim mix, so use criteria instead. Score candidates on how they route a drug between the pharmacy and medical benefits, how they derive HCPCS billing units, whether an expiring authorization blocks a booking or merely raises an alert, and their appeal overturn rate. Weight denial reporting heavily: 52% of practices that switched billing vendors cited missing denial reporting as the main reason.
Four repeat in every audit. Billing units copied from the vial or the dose instead of derived from the HCPCS code descriptor. Scheduling a refill or infusion outside the approved date range. Omitting JW or JZ on single dose container drug lines, required since July 1, 2023. And posting a payment that came in under the contracted rate without disputing it.
A percentage of collections, 3% to 6% at Luxen, with no setup or exit fee and 30 days notice on a monthly agreement. On $2 million of medical benefit collections that is $60,000 to $120,000 a year. The rate depends on how many benefits, states and 340B obligations are in scope, and it is set after a free 30 minute assessment.
About two weeks from signed BAA to claims being worked, and first recovered payments about three weeks after that. Denial rate moves inside 90 days and days in AR inside 120, because the AR change depends on claims submitted correctly after you start rather than on the backlog.
Yes, and the gap is where the money goes. Billing starts once the claim format is settled and ends at submission. Revenue cycle management starts at benefit investigation, before the drug is ordered, and ends at underpayment recovery, after the payment posts. Three of the seven stages sit outside billing entirely, including the one that decides whether this is a pharmacy or a medical claim.
A free 30 minute review of your AR ageing and denial reasons. We tell you what is recoverable and what it would take. No deck, no commitment, no fee.
Book a free revenue cycle assessment%20(1).avif)
